🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

‼️🚨Attention MS4s interested in Rad Onc! Spots are filling up fast for away rotations RadOncUH ⭐️Come join us! Apply through VSLO here (or with the QR!)👉🏼👉🏼  tinyurl.com/ytfua22f, using program code RAON 4002A! Supporting grants are available! 👉🏼👉🏼tinyurl.com/6esfmm5e

Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III Trials ascopubs.org/doi/abs/10.120… This study validates a novel

New Frontiers in PSMA Radioligand Therapy Is this the "hottest" session at ASCO #ASCO25 ?? ■ VIOLET: First-in-human trial of Terbium-161 ■ BULLSEYE: Lu-PSMA in oligo-metastatic disease ■ ENZA-p: Biomarkers ProsTIC PCF Science

This novel clinical and digital pathology AI biomarker identified 1/3 of clinical high risk localized patients who had excellent outcomes w/6 mo of ADT and no benefits to LTADT, potentially sparing such men the side effects of long term testosterone suppression.

Worth recognizing the plenary kick off of AUA is about devices the U.S. FDA rejected for cancer indication repeatedly. Instead of running the large phase 3 trials after the rejections the companies pivoted to de novo pathway to get approved effectively the same way a scalpel blade

Must be a better way!

Was the single port system the genesis of surgeon and/patient desire or benefit? If yes, would love to read the trials, even if small, to understand benefit to provider or patient. Or is it driven by the company to offer something different and thus increase sales? Practices

I have seen multiple papers on the prognostic impact of % pattern 4 on outcomes of treated patients (MSKCC, U of M, and other pubs). What is the best study showing this for AS patients?

💪💪💪💪

Missing some faculty but great meeting ⁦RadOncUH⁩ overlooking the University Circle skyline. Reflecting on past 4 years and what we have built is hard to believe. We are just getting started. Thank you to the best team I have ever worked with 🙏

Darren Poon Paul Sargos Vedang Murthy John Christodouleas Alison Tree 💙 Amar Kishan Priyamvada Maitre Simon Lo Shankar Siva HKSUO ESTRO Advanced Prostate Cancer Consensus Conference Nice work, Darren! Results look quite good for 5 fractions Himanshu Nagar Daniel E Spratt

Hands-only CPR and AED training by UH EMS and Harrington Heart & Vascular Institute at Park Synagogue Mitzvah-Good Deed Day. Pump and save a life! #UHProud

Promising result! Why not consider (lower dose SIB) hypofractionated nodal RT as well with primary SBRT? #ESTRO2025 #lcsm Drew Moghanaki Percy Lee MD

Stefano Arcangeli Neil Desai Thanks for listening to talk - few highlight slides here. Credit goes to great collaborators across trial group @ UMichigan, UPenn, Cleveland Clinic, U Colorado, Stony Brook, UCSF and UTSW

A rockstar radonc Dr. Andrew Loblaw once told me it’s always comforting when you find a study that confirms your biases. This gem I’ve been waiting for for a while now… thelancet.com/journals/lanon…

Honoured to had the opportunity to discuss the place of Adjuvant Radiotherapy for bladder Cancer and presenting the results of the Belgian trial supporting this approach! Motivated to proceed with our ongoing EFFORT trial! Flor Verghote Camille Berquin De Maeseneer Daan UZ Gent UGent

Can someone please explain why resection continues to occur so frequently when the overwhelming data supports radiosurgery for functional outcomes? Is there some other endpoint SRS is worse for?

Clear benefit of SBRT over low dose palliative RT. Shocked JCO approved of the conclusion stating only it “failed” at 1m. A small trial demonstrating 10% plus absolute CR benefits to SBRT that reach SS by 3m is impactful.